Gonadal function in males treated with cyclophosphamide for nephrotic syndrome

Area of Science:

• Nephrology
• Andrology
• Pharmacology

Background:

• Cyclophosphamide is a chemotherapy agent used to treat nephrotic syndrome.
• Long-term or high-dose cyclophosphamide therapy may pose risks to male reproductive health.

Purpose of the Study:

• To investigate the incidence and duration of gonadal dysfunction in male patients treated with cyclophosphamide for nephrotic syndrome.
• To evaluate the impact of treatment duration and dosage on reproductive outcomes.
• To assess the effectiveness of a limited treatment protocol in minimizing side effects.

Main Methods:

• Semen analysis was performed on 16 male patients treated with cyclophosphamide for nephrotic syndrome.
• Follow-up assessments were conducted 2 years and 9 months to 9 years and 1 month after therapy cessation.
• Treatment protocols were compared, focusing on a limited 8-week course (2.5 mg/kg/day).

Main Results:

• Azoospermia was observed in 3 patients and oligospermia in 7 patients.
• Prolonged treatment and higher total dosage correlated with increased gonadal dysfunction.
• No recovery of reproductive function was evident at long-term follow-up.
• A limited 8-week treatment course minimized gonadal dysfunction without significantly increasing relapse rates.

Conclusions:

• Cyclophosphamide therapy for nephrotic syndrome is associated with significant and potentially persistent male gonadal dysfunction.
• Limiting cyclophosphamide treatment to 8-week courses may be a viable strategy to reduce reproductive toxicity.
• Further research is warranted to optimize cyclophosphamide dosing and duration for nephrotic syndrome management.